HomeComparePOR vs GILD

POR vs GILD: Dividend Comparison 2026

POR yields 3.99% · GILD yields 2.34%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 POR wins by $40.4K in total portfolio value
10 years
POR
POR
● Live price
3.99%
Share price
$52.62
Annual div
$2.10
5Y div CAGR
30.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$69.5K
Annual income
$15,382.21
Full POR calculator →
GILD
GILD
● Live price
2.34%
Share price
$136.34
Annual div
$3.19
5Y div CAGR
17.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.1K
Annual income
$1,614.90
Full GILD calculator →

Portfolio growth — POR vs GILD

📍 POR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPORGILD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, POR + GILD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
POR pays
GILD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

POR
Annual income on $10K today (after 15% tax)
$339.22/yr
After 10yr DRIP, annual income (after tax)
$13,074.88/yr
GILD
Annual income on $10K today (after 15% tax)
$198.88/yr
After 10yr DRIP, annual income (after tax)
$1,372.67/yr
At 15% tax rate, POR beats the other by $11,702.21/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of POR + GILD for your $10,000?

POR: 50%GILD: 50%
100% GILD50/50100% POR
Portfolio after 10yr
$49.3K
Annual income
$8,498.55/yr
Blended yield
17.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GILD right now

POR
Analyst Ratings
6
Buy
15
Hold
2
Sell
Consensus: Hold
Price Target
$51.14
-2.8% upside vs current
Range: $46.00 — $58.00
Altman Z
1.0
Piotroski
5/9
GILD
Analyst Ratings
37
Buy
20
Hold
1
Sell
Consensus: Buy
Price Target
$158.71
+16.4% upside vs current
Range: $105.00 — $180.00
Altman Z
4.1
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

POR buys
5
GILD buys
14
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$GILD▲ Buy$1,001 - $15,0002026-01-27
Val Hoyle🏢 House$GILD▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$GILD▲ Buy$1,001 - $15,0002025-06-06
Josh Gottheimer🏢 House$GILD▼ Sell$1,001 - $15,0002025-05-14
Marjorie Taylor Greene🏢 House$GILD▲ Buy$1,001 - $15,0002025-05-05
Marjorie Taylor Greene🏢 House$GILD▲ Buy$1,001 - $15,0002025-05-05
John Boozman🏛 Senate$GILD▼ Sell$1,001 - $15,0002025-04-16
John Boozman🏛 Senate$GILD▼ Sell$1,001 - $15,0002025-04-16
Jefferson Shreve🏢 House$GILD▲ Buy$15,001 - $50,0002025-03-31
Carol Devine Miller🏢 House$GILD▲ Buy$1,001 - $15,0002025-03-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPORGILD
Forward yield3.99%2.34%
Annual dividend / share$2.10$3.19
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR30.2%17.3%
Portfolio after 10y$69.5K$29.1K
Annual income after 10y$15,382.21$1,614.90
Total dividends collected$43.5K$7.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$51.14$158.71

Year-by-year: POR vs GILD ($10,000, DRIP)

YearPOR PortfolioPOR Income/yrGILD PortfolioGILD Income/yrGap
1← crossover$11,220$519.61$10,974$274.45+$246.00POR
2$12,714$709.39$12,073$330.19+$641.00POR
3$14,583$978.20$13,316$398.20+$1.3KPOR
4$16,969$1,365.20$14,730$481.49+$2.2KPOR
5$20,089$1,933.01$16,345$583.87+$3.7KPOR
6$24,280$2,784.72$18,199$710.26+$6.1KPOR
7$30,075$4,095.41$20,340$866.96+$9.7KPOR
8$38,353$6,172.78$22,826$1,062.22+$15.5KPOR
9$50,617$9,578.59$25,731$1,306.80+$24.9KPOR
10$69,542$15,382.21$29,147$1,614.90+$40.4KPOR

POR vs GILD: Complete Analysis 2026

PORStock

Portland General Electric Company, an integrated electric utility company, engages in the generation, wholesale purchase, transmission, distribution, and retail sale of electricity in the state of Oregon. It operates six thermal plants, three wind farms, and seven hydroelectric facilities. As of December 31, 2021, the company owned an electric transmission system consisting of 1,274 circuit miles, including 287 circuit miles of 500 kilovolt line, 415 circuit miles of 230 kilovolt line, and 572 miles of 115 kilovolt line. It has 28,206 circuit miles of distribution lines. The company also purchases and sells wholesale natural gas in the United States and Canada. It serves approximately 917 thousand residential, commercial, and industrial customers in 51 cities. The company was founded in 1889 and is headquartered in Portland, Oregon.

Full POR Calculator →

GILDHealthcare

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Full GILD Calculator →
📬

Get this POR vs GILD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

POR vs SCHDPOR vs JEPIPOR vs OPOR vs KOPOR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.